EP Patent

EP2167476A2 — Novel hiv reverse transcriptase inhibitors

Assigned to Korea Research Institute of Chemical Technology KRICT · Expires 2010-03-31 · 16y expired

What this patent protects

The invention is related to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, ester, and/ or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

USPTO Abstract

The invention is related to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, ester, and/ or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Drugs covered by this patent

Patent Metadata

Patent number
EP2167476A2
Jurisdiction
EP
Classification
—
Expires
2010-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Korea Research Institute of Chemical Technology KRICT
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.